News
Apotex scores exclusive Canadian rights to testosterone therapy Nebido
Under the agreement, Apotex’s branded division, Searchlight Pharma, will seek regulatory approval and handle marketing and distribution in Canada
- By IPP Bureau
| February 07, 2026
Apotex, Canada’s largest pharmaceutical company, has secured exclusive Canadian rights to Nebido (testosterone undecanoate), a long-acting injectable therapy for male hypogonadism, through a licensing deal with global pain management leader Grünenthal.
Under the agreement, Apotex’s branded division, Searchlight Pharma, will seek regulatory approval and handle marketing and distribution in Canada. Grünenthal will receive an upfront payment, regulatory milestone payments, and a share of sales revenue.
“This marks an important step in Apotex's mission to broaden access to innovative medicines and advance our purpose as a Force for Health,” said Mark Nawacki, President of Searchlight Pharma.
“Nebido addresses a recognized need in men's health and represents our first entry into testosterone therapy — opening a meaningful new therapeutic area for Apotex while strengthening our branded portfolio and expanding our presence in specialty care.”
Jan Adams, Chief Commercial Officer at Grünenthal, added, “We are delighted to expand our partnership with Apotex and further strengthen the global presence of the brand. Through this agreement, we are providing a valuable and well-established brand that can benefit people living with testosterone deficiency in Canada.”
Grünenthal acquired global rights to Nebido in 2022 as part of a growth strategy that has included over €2 billion in mergers and acquisitions since 2017. The company continues to expand the footprint of its brands and create synergies across manufacturing, supply, logistics, and commercial operations.
The deal marks a deepening of the existing Apotex-Grünenthal partnership and underscores both companies’ commitment to improving Canadian patients’ access to important therapies.
